Shandong Boan Biotechnology Co., Ltd. (FRA:UJ9)

Germany · Delayed Price · Currency is EUR

0.3560

+0.0100 (2.89%)

Last updated: Oct 23, 2026, 3:25 PM CEST

Market Cap	226.77M -71.4%
Revenue (ttm)	80.46M -17.5%
Net Income	-12.42M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	397
Open	0.3600
Previous Close	0.3460
Day's Range	0.3560 - 0.3600
52-Week Range	0.2700 - 1.1700
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About FRA:UJ9

Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of post... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Employees 690

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol UJ9

Financial Performance

In 2025, FRA:UJ9's revenue was 784.82 million, an increase of 8.06% compared to the previous year's 726.32 million. Earnings were 7.14 million, a decrease of -90.24%.

Financial numbers in CNY Financial Statements